JHVEPhoto
GSK (NYSE:GSK) ranked fig 1 successful the 2022 Access to Medicine Index (ATMI), a study carried retired by a non-profit enactment that ranks 20 of the world's largest pharmaceutical companies connected advancement to amended entree successful 108 little income countries and focuses connected 83 diseases.
Johnson & Johnson (JNJ) was ranked second, AstraZeneca (AZN) came successful third, Novartis (NVS) was 4th and Merck KGaA (OTCPK:MKGAF) (OTCPK:MKKGY) took the 5th spot.
The study is published each 2 years by the Access to Medicine Foundation (AMF), a non-profit enactment funded by the Dutch and U.K. governments, the Bill & Melinda Gates Foundation, the Leona M. and Harry B. Helmsley Charitable Trust, and AXA Investment Managers.
"The 2022 Index finds that industry-wide betterment successful readying for entree and expanding entree strategies inactive overlooks low-income countries. Companies indispensable see the depths of their plans, spot of their proviso chains, and equity of their pricing strategies to scope the astir susceptible populations," said James Hazel, Research Program Manager for the 2022 Index, AMF.
GSK CEO Emma Walmsley noted that the British pharma elephantine ranked archetypal successful the ATMI for the eighth consecutive time.
GSK said it volition put an further £100M implicit the adjacent 10 years to enactment wellness strategy strengthening and entree initiatives successful little income countries.
"We person the largest R&D pipeline successful the manufacture addressing planetary wellness precedence diseases and person committed to put £1 cardinal implicit the adjacent decennary successful planetary wellness R&D," Walmsley added.
AMF, however, noted that though GSK retained the fig 1 spot, it was by a precise constrictive borderline up of J&J, which moved up from 3rd successful 2021. AstraZeneca recently joined the apical three, having risen from the seventh spot successful the erstwhile index.
AMF said that for the archetypal time, each 20 companies successful scope study an access-to-medicine strategy, with 19 integrating this into their wide firm strategy.
The enactment added that the scale besides saw companies expanding entree and strengthening transportation of their products successful in low-and middle-income countries (LMICs), with GSK, Pfizer (PFE) and Takeda (TAK) lasting out.
In addition, much companies person engaged successful voluntary licensing agreements, making their on-patent products disposable for generic manufacturing, AMF added.
Novartis (NVS) had licensed leukemia cause nilotinib to UN-backed Medicines Patent Pool.
Pfizer, Takeda, Sanofi (SNY), Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) and Roche (OTCQX:RHHBY) (OTCQX:RHHBF) were the others among the apical 10, retired of the 20.
English (US)